WALTHAM, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Tim Pearson as Chief Financial Officer. Mr. Pearson was most recently Executive Vice President and Chief Financial Officer of Catalyst Health Solutions, Inc., where he led the finance and strategic planning functions. Previously, Mr. Pearson served in a number of financial executive roles at MedImmune, the biologics division of AstraZeneca, including the positions of Executive Vice President and Chief Financial Officer, Vice President of Finance, and Treasurer. During his thirteen year tenure at MedImmue, prior to its acquisition by AstraZenca, Mr. Pearson was involved with commercial launches, marketing partnerships, in-licensing transactions and several acquisitions.
"I am very pleased to welcome Tim to TESARO and have him join our senior management team," said Lonnie Moulder, CEO of TESARO. "Tim's experience will support TESARO's transition to become an integrated commercial and development organization, and I look forward to working closely with him."
Mr. Pearson has more than 20 years of finance and executive leadership experience. He holds a B.S. in Business Administration from the University of Delaware, a M.S. in finance from Loyola University Maryland and a B.S. in accounting from the University of Maryland University College. He is also a Certified Public Accountant.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.
CONTACT: Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or firstname.lastname@example.org